Eton Pharmaceuticals (NASDAQ:ETON) Given New $18.00 Price Target at Craig Hallum

Eton Pharmaceuticals (NASDAQ:ETON) had its price target boosted by Craig Hallum from $15.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Separately, HC Wainwright increased their target price on Eton Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday.

Eton Pharmaceuticals Price Performance

ETON stock opened at $12.01 on Wednesday. The firm has a 50 day simple moving average of $11.57 and a two-hundred day simple moving average of $7.32. The stock has a market cap of $312.87 million, a PE ratio of -54.59 and a beta of 1.38. Eton Pharmaceuticals has a one year low of $3.03 and a one year high of $15.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ETON. Parkman Healthcare Partners LLC boosted its stake in shares of Eton Pharmaceuticals by 2.8% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 260,226 shares of the company’s stock valued at $1,561,000 after purchasing an additional 7,029 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Eton Pharmaceuticals in the 3rd quarter worth $54,000. Jane Street Group LLC bought a new stake in Eton Pharmaceuticals in the third quarter worth $90,000. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Eton Pharmaceuticals by 86.6% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Eton Pharmaceuticals by 13.5% during the third quarter. Geode Capital Management LLC now owns 272,696 shares of the company’s stock valued at $1,637,000 after buying an additional 32,365 shares during the last quarter. 27.86% of the stock is currently owned by institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.